MedTrace Logo

Long-term Durability Study of Collagenase Clostridium Histolyticum (CCH)

NCT04381117 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 7

Last updated 2024-01-02

No results posted yet for this study

Summary

This study will evaluate the long-term safety and duration of efficacy of CCH in the treatment of women with cellulite. This study will be a single day evaluation, approximately 48 months after the first dose of study drug was received in the EN3835-201.

Conditions

  • Edematous Fibrosclerotic Panniculopathy

Interventions

DRUG

Previously Treated with EN3835

No treatment to be administered - Observational only

Sponsors & Collaborators

  • Endo Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Karen Chajko · Endo Pharmaceuticals

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-06
Primary Completion
2020-06-22
Completion
2020-06-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04381117 on ClinicalTrials.gov